133 related articles for article (PubMed ID: 17761832)
1. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Leleu X; Jia X; Runnels J; Ngo HT; Moreau AS; Farag M; Spencer JA; Pitsillides CM; Hatjiharissi E; Roccaro A; O'Sullivan G; McMillin DW; Moreno D; Kiziltepe T; Carrasco R; Treon SP; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
Blood; 2007 Dec; 110(13):4417-26. PubMed ID: 17761832
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
Li Z; Tan F; Liewehr DJ; Steinberg SM; Thiele CJ
J Natl Cancer Inst; 2010 Jun; 102(11):758-70. PubMed ID: 20463309
[TBL] [Abstract][Full Text] [Related]
3. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
4. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS; Jia X; Patterson CJ; Roccaro AM; Xu L; Sacco A; O'Connor K; Soumerai J; Ngo HT; Hatjiharissi E; Hunter ZR; Ciccarelli B; Manning R; Ghobrial IM; Leleu X; Treon SP
Br J Haematol; 2008 Sep; 142(5):775-85. PubMed ID: 18537966
[TBL] [Abstract][Full Text] [Related]
5. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Li Z; Oh DY; Nakamura K; Thiele CJ
Cancer; 2011 Dec; 117(23):5412-22. PubMed ID: 21590687
[TBL] [Abstract][Full Text] [Related]
6. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
7. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
Fulciniti M; Amodio N; Bandi RL; Munshi M; Yang G; Xu L; Hunter Z; Tassone P; Anderson KC; Treon SP; Munshi NC
Blood; 2014 Apr; 123(17):2673-81. PubMed ID: 24622324
[TBL] [Abstract][Full Text] [Related]
8. Update on therapeutic options in Waldenström macroglobulinemia.
Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
[TBL] [Abstract][Full Text] [Related]
9. Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.
Boutilier AJ; Huang L; Elsawa SF
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232447
[TBL] [Abstract][Full Text] [Related]
10. M2-like macrophages transplantation protects against the doxorubicin-induced heart failure via mitochondrial transfer.
Liu Y; Wu M; Zhong C; Xu B; Kang L
Biomater Res; 2022 Apr; 26(1):14. PubMed ID: 35410296
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
Tomowiak C; Poulain S; Herbaux C; Perrot A; Mahé B; Morel P; Aurran T; Tournilhac O; Leprêtre S; Assaad S; Villemagne B; Casasnovas O; Nollet D; Roos-Weil D; Chevret S; Leblond V
Blood Adv; 2021 May; 5(9):2438-2446. PubMed ID: 33961019
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Matissek SJ; Han W; Karbalivand M; Sayed M; Reilly BM; Mallat S; Ghazal SM; Munshi M; Yang G; Treon SP; Walker SR; Elsawa SF
Epigenomics; 2021 Jan; 13(2):129-144. PubMed ID: 33356554
[No Abstract] [Full Text] [Related]
13. Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia.
Han W; Matissek SJ; Jackson DA; Sklavanitis B; Elsawa SF
Oncotarget; 2019 May; 10(36):3400-3407. PubMed ID: 31164961
[TBL] [Abstract][Full Text] [Related]
14. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.
Bouyssou JM; Liu CJ; Bustoros M; Sklavenitis-Pistofidis R; Aljawai Y; Manier S; Yosef A; Sacco A; Kokubun K; Tsukamoto S; Perilla Glen A; Huynh D; Castillo JJ; Treon SP; Leblond V; Hermine O; Roccaro AM; Ghobrial IM; Capelletti M
PLoS One; 2018; 13(10):e0204589. PubMed ID: 30286096
[TBL] [Abstract][Full Text] [Related]
15. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
Ni H; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Hitoshi Y; Ansell SM; Treon SP; Thomas SK; Lee HC; Wang Z; Davis RE; Orlowski RZ
Clin Cancer Res; 2018 Dec; 24(24):6408-6420. PubMed ID: 30126942
[TBL] [Abstract][Full Text] [Related]
16. Waldenstrom's Macroglobulinemia: An Update.
Mazzucchelli M; Frustaci AM; Deodato M; Cairoli R; Tedeschi A
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018004. PubMed ID: 29326801
[TBL] [Abstract][Full Text] [Related]
17.
Herbaux C; Bertrand E; Marot G; Roumier C; Poret N; Soenen V; Nibourel O; Roche-Lestienne C; Broucqsault N; Galiègue-Zouitina S; Boyle EM; Fouquet G; Renneville A; Tricot S; Morschhauser F; Preudhomme C; Quesnel B; Poulain S; Leleu X
Oncotarget; 2017 Aug; 8(34):57451-57459. PubMed ID: 28924457
[TBL] [Abstract][Full Text] [Related]
18. Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.
Han W; Jackson DA; Matissek SJ; Misurelli JA; Neil MS; Sklavanitis B; Amarsaikhan N; Elsawa SF
J Immunol; 2017 Jun; 198(11):4481-4489. PubMed ID: 28461568
[TBL] [Abstract][Full Text] [Related]
19. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
